Accurate risk classification at diagnosis anchors every subsequent treatment decision in high-risk neuroblastoma. It shapes induction intensity, trial eligibility, and the choice of immunotherapy at relapse. The 2021 Children's Oncology Group revision of the INRG framework is now the operative standard for pretreatment stratification across North American cooperative group trials.
The framework rests on imaging-based staging, a defined set of prognostic markers, and a 2021 update that reshaped stratification of MYCN-non-amplified patients. Emerging biomarkers like ALK status are positioned to enter the next iteration. Half of neuroblastoma is classified as high-risk, so the classifier shapes treatment intensity for a substantial share of every program's caseload.
Why Pretreatment Staging Anchors the INRG Framework
The shift from the International Neuroblastoma Staging System to the INRG Staging System was methodological but consequential. The older system classified disease by surgical findings, particularly resection completeness. Two patients with biologically identical tumors could receive different stages based on surgical approach.
The INRG Staging System uses imaging-based pretreatment assessment built around image-defined risk factors. These are anatomical features visible on diagnostic imaging that signal vascular proximity, compartment infiltration, or encasement. The shift removed surgical variability from staging and aligned classification with the underlying biology.
The four stages are L1, a localized tumor without image-defined risk factors; L2, a localized tumor with one or more such factors; M, distant metastatic disease excluding stage MS; and MS, metastatic disease in children under 18 months confined to skin, liver, or bone marrow. Image-defined risk factors carry independent prognostic weight beyond stage assignment. Two patients at the same stage can follow different trajectories.
The metastatic pattern documented at staging shapes downstream therapy choices. Among patients with metastatic disease, 70 percent of metastases involve bone marrow and 55 percent involve cortical bone. The pattern predicts which patients will eventually be candidates for therapies indicated for bone or bone marrow involvement at relapse.
Which Markers Drive High-Risk Neuroblastoma Assignment
The INRG schema combines INRG Staging System stage, age at diagnosis, MYCN status, segmental chromosomal aberrations, ploidy, tumor histology, and grade of differentiation for neuroblastoma. The schema assigns patients across pretreatment risk groups from very low to high risk. No single factor decides risk alone, but MYCN amplification overrides most others when present.
MYCN amplification remains the strongest adverse prognostic marker in the schema. It reliably predicts aggressive disease across patient subsets. Its presence pushes most patients into the high-risk category regardless of other features, even in localized disease or favorable histology.
Age at diagnosis is the second-most reliable prognostic divider. Children diagnosed before 18 months generally fare better than older children with comparable disease. The 18-month threshold reflects underlying biology rather than an arbitrary cutoff.
Segmental chromosomal aberrations at 1p and 11q have emerged as significant adverse markers in MYCN-non-amplified patients. The finding was central to the 2021 update. DNA ploidy works similarly, with hyperdiploid tumors in infants carrying a favorable prognosis compared with diploid disease.
How the 2021 COG Classifier Update Changed High-Risk Neuroblastoma Risk Assignment
The revised 2021 COG neuroblastoma risk classifier (version 2), published by Irwin et al. in the Journal of Clinical Oncology, made two structural changes that are now operative for all COG trial eligibility and treatment assignment. It replaced surgical staging with the INRG Staging System, aligning North American practice with international standards. It also incorporated segmental chromosomal aberrations at 1p and 11q as genomic biomarkers alongside MYCN, ploidy, and histology.
The 11q addition reflected evidence of independent prognostic impact in MYCN-non-amplified patients. The subset had been under-stratified by version 1. Version 2 reassigned a small but meaningful share of previously non-high-risk patients to high-risk, and the reclassification flowed in both directions.
The bidirectional movement reflects greater precision rather than indiscriminate escalation. Some patients moved up because segmental chromosomal aberrations sharpened the picture of previously favorable-looking biology. Others moved down because the new framework recognized molecular features the older one missed. Clinicians using version 1 criteria should confirm they are applying version 2, since current COG trial eligibility depends on it.
Two-thirds of patients with high-risk disease do not achieve a complete metastatic response during induction. Two-fifths relapse despite intensive multimodal frontline therapy. The classifier shapes initial intensity, but those induction and relapse rates shape the downstream therapeutic landscape.
How Risk Assignment Shapes Treatment Intensity and Naxitamab Eligibility
A high-risk assignment under the 2021 classifier triggers the most intensive treatment pathway in pediatric oncology. Accurate classification puts each child into the protocol their biology warrants. The bidirectional movement under version 2 means some patients now correctly receive lower-intensity care.
The clinical stakes cut both ways. Overclassifying a low-risk child exposes them to needless toxicity and long-term late effects. Underclassifying a high-risk child delays aggressive treatment and may also affect eligibility for immunotherapy options available at later disease states.
The relapsed and refractory subset defines the population for which DANYELZA is indicated. DANYELZA, in combination with GM-CSF, is approved for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Eligible patients must have demonstrated a partial response, minor response, or stable disease to prior therapy. The accelerated approval rests on overall response rate and duration of response, with continued approval potentially contingent on confirmatory trials.
Knowing at diagnosis which patients present with bone and bone marrow disease informs both initial planning and downstream therapy choices. Assessment of bone and bone marrow involvement requires both MIBG imaging and biopsy. The Curie score derived from MIBG carries prognostic implications, and an absolute Curie score of 0 to 2 prior to transplant is more clinically prognostic than relative reduction from baseline.
Where the Classifier Is Heading: Emerging Biomarkers
The 2021 update identified additional biomarkers under prospective evaluation for future iterations. ALK mutation and amplification fall outside the current schema but carry prognostic and therapeutic weight. ALK alterations occur in roughly 10 percent of neuroblastoma cases and represent the most established actionable molecular target in the disease.
The Children's Oncology Group has begun integrating ALK inhibition with lorlatinib into frontline protocols for patients with ALK-altered disease. ALK status is expected to inform risk assignment in future classifier versions as the data matures.
Telomerase maintenance mechanisms, including TERT promoter rearrangements and ATRX mutations, are also being collected prospectively. The markers capture biology in MYCN-non-amplified disease that current classifiers miss. Integration into a future classifier is an active area of consortium work.
Clinicians should ensure their molecular profiling panels capture ALK, TERT, and ATRX status at diagnosis. The data collected now determines which patients qualify for next-generation trials. Institutions without the testing infrastructure will lag behind both eligibility and prognostic accuracy.
Clinical Resources for High-Risk Neuroblastoma
Accurate INRG classification under the 2021 COG framework anchors treatment decisions, trial eligibility, and immunotherapy choices throughout the high-risk neuroblastoma disease course. The framework rewards clinicians who understand not just the categories but the biology and evidence behind them. Confirming the version 2 application and capturing emerging biomarkers at diagnosis positions your patients for both current standards and the next iteration of the classifier.
Full prescribing information for DANYELZA, HCP support tools, and clinical resources for managing relapsed and refractory high-risk neuroblastoma are available at DanyelzaHCP.com. For the current COG trial framework and eligibility criteria under the 2021 classifier, consult COG protocol documentation and the INRG consortium resources.
Sources
- DANYELZA (naxitamab-gqgk) [package insert]. New York, NY: Y-mAbs Therapeutics, Inc.; 2024. https://labeling.ymabs.com/danyelza
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580-2587. https://pubmed.ncbi.nlm.nih.gov/28471719/
- DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181-189. https://pubmed.ncbi.nlm.nih.gov/10363850/
- Garaventa A, Poetschger U, Valteau-Couanet D, et al. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23):2552-2563. https://ascopubs.org/doi/10.1200/JCO.20.03144
- Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children's Oncology Group. Eur J Cancer. 2019;112:66-79.
- Yanik GA, Parisi MT, Naranjo A, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59(3):502-508. https://jnm.snmjournals.org/content/59/3/502
